Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.

Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.

Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.

PMID:
24676847
[PubMed - in process]
2.

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.

Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP.

Bone. 2014 Jan;58:48-54. doi: 10.1016/j.bone.2013.10.006. Epub 2013 Oct 17.

PMID:
24141036
[PubMed - indexed for MEDLINE]
Free Article
3.

Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.

Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P, Wagman RB, Hall JW, Bolognese MA, Benhamou CL.

Obstet Gynecol. 2013 Jun;121(6):1291-9. doi: 10.1097/AOG.0b013e318291718c.

PMID:
23812464
[PubMed - indexed for MEDLINE]
4.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
[PubMed - indexed for MEDLINE]
5.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.

J Bone Miner Res. 2010 Jan;25(1):72-81. doi: 10.1359/jbmr.090716.

PMID:
19594293
[PubMed - indexed for MEDLINE]
6.

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

Epstein S, Jeglitsch M, McCloskey E.

Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review.

PMID:
19835464
[PubMed - indexed for MEDLINE]
7.

Efficacy and safety of monthly ibandronate in men with low bone density.

Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.

Bone. 2010 Apr;46(4):970-6. doi: 10.1016/j.bone.2009.12.034. Epub 2010 Jan 6.

PMID:
20060082
[PubMed - indexed for MEDLINE]
8.

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group.

J Bone Miner Res. 2004 Jan;19(1):11-8.

PMID:
14753731
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.

Bone. 2009 Mar;44(3):418-22. doi: 10.1016/j.bone.2008.09.011. Epub 2008 Oct 7.

PMID:
18950736
[PubMed - indexed for MEDLINE]
10.

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.

Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY.

Clin Rheumatol. 2008 Aug;27(8):955-60. doi: 10.1007/s10067-007-0824-6. Epub 2008 Jan 8.

PMID:
18180976
[PubMed - indexed for MEDLINE]
11.

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.

Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD.

Ann Rheum Dis. 2006 May;65(5):654-61. Epub 2005 Dec 8. Erratum in: Ann Rheum Dis. 2008 Feb;67(2):280.

PMID:
16339289
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

PMID:
15231010
[PubMed - indexed for MEDLINE]
13.

Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.

Sebba AI.

Clin Ther. 2008 Mar;30(3):443-52. doi: 10.1016/j.clinthera.2008.03.008. Review. Erratum in: Clin Ther. 2008 Jun;30(6):1177-8.

PMID:
18405784
[PubMed - indexed for MEDLINE]
14.

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J; Amg Bone Loss Study Group.

Bone. 2008 Aug;43(2):222-9. doi: 10.1016/j.bone.2008.04.007. Epub 2008 Apr 26.

PMID:
18539106
[PubMed - indexed for MEDLINE]
15.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
[PubMed - indexed for MEDLINE]
16.

Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.

Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L; ONCE trial group.

Scand J Rheumatol. 2012 Aug;41(4):260-6. doi: 10.3109/03009742.2012.664647.

PMID:
22803768
[PubMed - indexed for MEDLINE]
17.

Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.

Nakamura T, Matsumoto T, Sugimoto T, Shiraki M.

Osteoporos Int. 2012 Mar;23(3):1131-40. doi: 10.1007/s00198-011-1786-8. Epub 2011 Sep 17.

PMID:
21927920
[PubMed - indexed for MEDLINE]
18.

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.

Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM.

J Clin Endocrinol Metab. 2014 May;99(5):1694-700. doi: 10.1210/jc.2013-4440. Epub 2014 Feb 11.

PMID:
24517156
[PubMed - indexed for MEDLINE]
19.

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.

Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG.

J Bone Miner Res. 2009 Jan;24(1):153-61. doi: 10.1359/jbmr.080901.

PMID:
18767928
[PubMed - indexed for MEDLINE]
20.

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.

Miller PD, Epstein S, Sedarati F, Reginster JY.

Curr Med Res Opin. 2008 Jan;24(1):207-13.

PMID:
18042311
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk